SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/50

Date: 8th September 2025

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 – Updates of Application under the Production Linked Incentive (PLI) Scheme

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company would like to intimate an update in respect of the approval granted to the Company for Production Linked Incentive (PLI) Scheme.

The letter as received from the department of Pharmaceuticals under Ministry of Chemicals and Fertilizers is enclosed herewith.

Request you to take the same on your record.

Thanks & Regards,

Yours faithfully,

For, **Sudarshan Pharma Industries Limited**

Hemal Mehta
Chairman & Managing Director

Encl: As above

By Speed Post and email

सं/No. G-30013/01/2023-Scheme

भारत सरकार /Government of India

रसायन और उर्वरक मंत्रालय /Ministry of Chemicals and Fertilizers

औषध विभाग /Department of Pharmaceuticals

उद्योग भवन, नई दिल्ली-110 001
Udyog Bhawan, New Delhi-110 001
Dated 28th August 2025

To,
Sudarshan Pharma Industries Limited
through its Director, Mr Hemal Mehta
301, 3rd Floor, Sudarshan House
Aura Biplex, above Kalyan Jewellers
S V Road, Borivali (West)
Maharashtra–400 092
[Email: sudarshangroupexports@gmail.com, hemal@sudarshangrp.com]

Subject: Request for change in greenfield location and revision in scheduled commercial operation date under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) in India -regarding

Reference:

i. *Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) in India (hereinafter referred to as PLI Scheme for Bulk Drugs) notified vide Gazette Notification No. 31206/16/2020-policy, dated 21.7.2020 and PLI Scheme Guidelines, Notification dated 26.7.2022, issued thereunder and as amended from time to time.*

ii. *Approval letter vide reference no. IFCI/CASD/DoP/PLI–211216017 dated 14.12.2021.*

iii. *Approval letter vide reference no. IFCI/CASD/DoP/PLI –230222003 dated 22.2.2023.*

iv. *Revision in scheduled commercial operation date letter under the PLI Bulk Drug scheme dated 18.9.2024*

v. *Addressee's letter dated 18.6.2025 requesting change of greenfield location and grant of extension in scheduled commercial operation date, under the PLI Bulk Drug scheme*

Sir,

Reference is invited to approval letter dated 14.12.2021 and 22.2.2023 granted under the PLI Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) in India, for eligible product Vitamin B6 and Vitamin B1, respectively. The original scheduled commercial operation date for greenfield projects of Vitamin B6 and Vitamin B1 was 30.8.2023 and 31.3.2024, respectively. Subsequently,

the competent authority granted extension to the scheduled commercial operation date for the greenfield projects of Vitamin B6 and Vitamin B1 up to 31.3.2025.

2. However, *vide* representation dated 18.6.2025, which has been received in the Department on 25.06.2025, it was intimated by you that the projects will not get commissioned by the approved scheduled date, citing issues of local resistance. Two alternatives have been proposed by you in your representation, i.e., acquisition of two existing non-functional units in GIDC or setting up greenfield projects through fresh land allotment in GIDC for relocation. In your representation, you have also requested extension of the scheduled commercial operation date up to 30.6.2026 by use of existing units in GIDC and up to 31.12.2027 for setting up fresh projects on a new land. Further you have requested to grant extension in incentive claim period up to March 2031 if approval is granted for setting up projects in existing facilities and up to March 2032, in case approval is granted for setting up greenfield projects.

3. In this regard, the competent authority has approved the change in location of the greenfield projects from MIDC, Maharashtra to GIDC, Gujarat for setting up greenfield projects, along with the revision of the scheduled commercial operation date for the bulk drugs, Vitamin B1 (chemical synthesis route) and Vitamin B6. This approval is subject to the condition that the projects for aforementioned products will be commissioned by 31.12.2027. All other criteria for claiming the incentive shall remain unchanged and will continue to be applicable as per the scheme guidelines and the approval letter.

4. This issues with the approval of competent authority.

Yours faithfully,

28/5/25

(सुहास भुइयां)(Suhas Bhuyan)
अवर सचिव, भारत सरकार
Under Secretary to the Govt. of India
दूरभाष/Tel.: 011-23062531
Email: US-PharmaSchemes@pharma-dept.gov.in